A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
Animals
Antiviral Agents
/ pharmacology
Cathepsin L
/ antagonists & inhibitors
Cell Line, Tumor
Chlorocebus aethiops
Cysteine Proteinase Inhibitors
/ pharmacology
Humans
Microbial Sensitivity Tests
Phenylalanine
/ pharmacology
Piperazines
/ pharmacology
Protein Domains
Proteolysis
SARS-CoV-2
/ drug effects
Spike Glycoprotein, Coronavirus
/ chemistry
Tosyl Compounds
/ pharmacology
Vero Cells
Virus Internalization
/ drug effects
Journal
ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906
Informations de publication
Date de publication:
16 04 2021
16 04 2021
Historique:
pubmed:
1
4
2021
medline:
30
4
2021
entrez:
31
3
2021
Statut:
ppublish
Résumé
Host-cell cysteine proteases play an essential role in the processing of the viral spike protein of SARS coronaviruses. K777, an irreversible, covalent inactivator of cysteine proteases that has recently completed phase 1 clinical trials, reduced SARS-CoV-2 viral infectivity in several host cells: Vero E6 (EC
Identifiants
pubmed: 33787221
doi: 10.1021/acschembio.0c00875
doi:
Substances chimiques
Antiviral Agents
0
Cysteine Proteinase Inhibitors
0
Piperazines
0
Spike Glycoprotein, Coronavirus
0
Tosyl Compounds
0
spike protein, SARS-CoV-2
0
N-pip-phenylalanine-homophenylalanine-vinyl sulfone phenyl
320A4L58IZ
Phenylalanine
47E5O17Y3R
Cathepsin L
EC 3.4.22.15
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-650Subventions
Organisme : NIAID NIH HHS
ID : N01AI30048
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Commentaires et corrections
Type : UpdateOf